INDUSTRY KEYWORDS: Oncology
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
– Trial Designed to Support an Accelerated Approval Application in the U.S. – 28/09/2021 — BOTHELL, Wash. — (BUSINESS WIRE) Seagen Inc. (Nasdaq: SGEN) today announced it completed patient enrollment […]